Pharmaceuticals roundup 2023

Legislation caused consternation for the pharmaceutical industry in both the EU and the US in 2023. First, the EU’s delayed draft pharmaceutical legislation was finally published in late April. Notable proposals include a reduction in the number of scientific committees at the European Medicines Agency (EMA). The EMA would have to be notified more quickly about any impending product withdrawals or shortages, and companies will also have to hold higher inventories of essential medicines. Other provisions include incentives for endeavours such as developing new antibodies.